Characteristics of patients and main results
| Variable | n=53 |
|---|---|
| Age (years), mean±SD | 51.5±15.7 |
| Male gender, n (%) | 28 (52.8) |
| Smokers, n (%) | |
| Never | 50 (94.3) |
| Current | 2 (3.8) |
| Ex | 1 (1.9) |
| Type of disease, n (%) | |
| Crohn's disease | 34 (64.2) |
| Ulcerative colitis | 19 (35.8) |
| Duration of disease (years), mean±SD | 13.6±9.4 |
| Localisation of the disease, n (%) | |
| Crohn's disease | |
| Ileal | 3 (8.8) |
| Ileocolic | 26 (76.5) |
| Colic | 4 (11.8) |
| Upper gastrointestinal tract* | 1 (2.9) |
| Perianal disease | 7 (20.6) |
| Ulcerative colitis | |
| Proctitis | 0 (0.0) |
| Left-sided | 6 (31.6) |
| Extensive | 13 (68.4) |
| Behaviour (Crohn's disease), n (%) | |
| Inflammatory | 16 (47.1) |
| Stricturing | 17 (50.0) |
| Fistulising | 1 (2.9) |
| Previous resections (Crohn's disease), n (%) | 21 (61.8) |
| Previous biological treatments | |
| Yes | 43 (81.1) |
| No (naïve to biologics) | 10 (18.9) |
| Steroid-dependent, n (%) | 51 (96.2) |
| IBD-associated SpA | |
| No history | 31 (58.5) |
| History (inactive at initiation of VDZ) | 8 (15.1) |
| Active at initiation of VDZ | 14 (26.4) |
| Peripheral arthropathy | 12 (85.7) |
| Axial and peripheral arthropathy | 2 (14.3) |
| Clinical benefit on SpA following initiation of VDZ (n=14) | |
| No clinical benefit | 8/14 (57.1) |
| Improvement | 6/14 (42.9) |
| New onset/exacerbation of SpA induced by VDZ | 0 |
*In addition to an ileocolic localisation.
IBD, inflammatory bowel disease; SpA, spondyloarthritis; VDZ, vedolizumab.